These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 24524212)

  • 21. Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
    Carulli G; Baratè C; Marini A; Ottaviano V; Cervetti G; Fontanelli G; Guerrini F; Arici R; Guerri V; Di Paolo A; Polillo M; Ferreri MI; Galimberti S; Petrini M
    Hematol Oncol; 2015 Dec; 33(4):250-2. PubMed ID: 25256816
    [No Abstract]   [Full Text] [Related]  

  • 22. Variation in Adherence Measures to Imatinib Therapy.
    Yanamandra U; Malhotra P; Sahu KK; Sushma Y; Saini N; Chauhan P; Gill J; Rikhi D; Khadwal A; Prakash G; Lad D; Suri V; Kumari S; Varma N; Varma S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia.
    Batrani M; Salhotra M; Kubba A; Agrawal M
    Indian J Dermatol Venereol Leprol; 2016; 82(6):727-729. PubMed ID: 27716725
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
    Thapa M; Chaturvedi A
    Postgrad Med J; 2020 May; 96(1135):296-297. PubMed ID: 31672761
    [No Abstract]   [Full Text] [Related]  

  • 26. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
    Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
    Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
    Scott AD; Lee M; Kubba F; Chu A
    Clin Exp Dermatol; 2015 Dec; 40(8):926-7. PubMed ID: 25266712
    [No Abstract]   [Full Text] [Related]  

  • 28. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.
    Ganesan P; Sagar TG; Dubashi B; Rajendranath R; Kannan K; Cyriac S; Nandennavar M
    Am J Hematol; 2011 Jun; 86(6):471-4. PubMed ID: 21538468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
    Rudzki J; Wolf D
    Expert Rev Hematol; 2011 Apr; 4(2):153-9. PubMed ID: 21495925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
    Al-Dewik NI; Morsi HM; Samara MM; Ghasoub RS; Gnanam CC; Bhaskaran SK; Nashwan AJ; Al-Jurf RM; Ismail MA; AlSharshani MM; AlSayab AA; Ben-Omran TI; Khatib RB; Yassin MA
    Clin Med Insights Oncol; 2016; 10():95-104. PubMed ID: 27721664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
    Marin D
    Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.
    Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D
    Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.
    Davis TC; Arnold CL; Mills G; Lesser GJ; Brown WM; Schulz R; Weaver KE; Pawloski PA
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
    Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
    Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
    Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare Professionals' Perspectives of Patients' Experiences of the Self-Management of Type 2 Diabetes in the Rural Areas of Pakistan: A Qualitative Analysis.
    Ansari RM; Harris M; Hosseinzadeh H; Zwar N
    Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response.
    García-Queiruga M; Martínez-López LM; Martín-Herranz MI; Seoane-Pillado T; Fernández-Gabriel E; Calleja-Chuclá T
    Farm Hosp; 2016 May; 40(3):141-9. PubMed ID: 27145384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.